Vivani Medical, Inc. Announces Pricing of Common Stock Offering
VANIALAMEDA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the pricing of a best efforts registered direct offering of 1,689,200 shares of its common stock at an offering price of $1.48 per share and concurrent private placement of 1,351,351 shares of its common stock at an offering price of $1.48 per share purchased by Gregg Williams, the Chairman of the Company’s board of directors. The registered offering and the private placement were priced “at-the-market” under the rules and regulations of The Nasdaq Stock Market LLC. The gross proceeds to the Company from the registered offering and private placement are expected to be approximately $4.5 million, before deducting placement agent fees and estimated offering expenses. The registered offering and private placement are expected to close on or about January 27, 20
Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
VANIALAMEDA, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and conduct partnering meetings at the H.C. Wainwright 27th Annual Global Investment Conference, taking place from September 8-10, 2025 in New York, New York.
Vivani Medical Announces The Appointment Of Anthony Baldor As Chief Financial Officer
VANIHC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target
VANIVivani Medical Q1 EPS $(0.11) Misses $(0.10) Estimate
VANIHC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target
VANIVivani Medical Expands Collaboration With Okava Pharmaceuticals To Include Dogs In Development Of OKV-119, A Long-Acting Glp-1 Therapy For Weight Management, Diabetes and Other Cardiometabolic Conditions
VANIEXCLUSIVE: Vivani Medical Collaborates With Okava To Expand Development Of GLP-1 Therapy For Dogs
VANIVivani Medical and Okava expand GLP-1 therapy research to dogs, aiming to advance long-acting treatments for cardiometabolic conditions.
EXCLUSIVE: Vivani Medical Tells Benzinga 'Over half of all dogs in the United States today are overweight or obese, placing them at increased risk for chronic diseases, metabolic decline and shortened lifespans'
VANIEXCLUSIVE: Vivani Medical Tells Benzinga Co. And Okava Expand Collaboration To Develop OKV-119 For Dogs, Targeting Metabolic Health And Longevity
VANIHC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target
VANIVivani Medical Q4 2024 GAAP EPS $(0.11), Inline, As Of December 31, 2024, Vivani Had Cash, Cash Equivalents And Restricted Cash Totaling $19.7M, Additional $8.25M Equity Financing Which Secures Solid Financial Position Into Q2 Of 2026
VANIVivani Medical Plans Private Placement Of 7.37M Shares At $1.12 Per Share, Expected To Result In Gross Proceeds Of $8.25M
VANIHC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target
VANIEXCLUSIVE: Vivani Medical Tells Benzinga 'NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing'
VANIEXCLUSIVE: Vivani Medical Tells Benzinga 'NanoPortal technology successfully delivers semaglutide, the active ingredient in Ozempic/Wegovy, in a preclinical study with NPM-139'
VANIEXCLUSIVE: Vivani Medical Tells Benzinga Co. Announces Preclinical Weight Loss Data For NPM-139 Semaglutide Implant, With Potential For Once-Year Dosing
VANIEXCLUSIVE: Vivani Medical Tells Benzinga 'NPM-115 has demonstrated comparable preclinical weight loss to injections of semaglutide, the active ingredient in Ozempic/Wegovy'
VANIEXCLUSIVE: Vivani Medical Tells Benzinga 'Rapid full study enrollment with all 24 subjects initiating the 8-week run-in period within four weeks; top-line study results expected in mid-2025'
VANIEXCLUSIVE: Vivani Medical Tells Benzinga 'Miniature, twice-yearly GLP-1 (exenatide) implant under development for chronic weight management'
VANIEXCLUSIVE: Vivani Medical Tells Benzinga Co Achieves First Patient Implant And Full Enrollment In The First-in-Human Clinical Trial Of GLP-1 Implant NPM-115 In Obese Or Overweight Adults
VANIHC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target
VANIEXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Business To Create Better Focus On Individual Entities And Shareholder Value
VANIVivani Medical plans to spin off Cortigent into a separate public company, aiming to expand neurostimulation technology while focusing on its drug implants.
EXCLUSIVE: Vivani Medical Tells Benzinga 'The strategic goal of this transaction is to create two focused companies dedicated to driving current and future value in their respective therapeutic areas of expertise'
VANIEXCLUSIVE: Vivani Medical Tells Benzinga 'Spin-off will allow Vivani to focus on developing miniature, ultra long-acting GLP-1 implants for chronic weight management and type 2 diabetes with once or twice-yearly administration'
VANIEXCLUSIVE: Vivani Medical Tells Benzinga 'Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent shareholders'
VANIEXCLUSIVE: Vivani Medical Tells Benzinga Co. Announces Intent To Spin Off Cortigent Neurostimulation Business
VANIEXCLUSIVE: Vivani Medical Initiates First Human Clinical Trial With GLP-1 Implant For Weight Loss In Australia
VANIVivani Medical launches first-in-human trial of its exenatide implant in Australia, aiming to support chronic weight management with innovative GLP-1 technology.
EXCLUSIVE: Vivani Medical Tells Benzinga 'Study represents the first clinical application of NanoPortal, the Company's proprietary drug implant platform technology'
VANIEXCLUSIVE: Vivani Medical Tells Benzinga 'NPM-115 clinical program utilizes a miniature, GLP-1 (exenatide) implant designed to provide comparable efficacy to semaglutide, with twice-yearly administration'
VANIEXCLUSIVE: Vivani Medical Tells Benzinga Co. Announces Initiation Of First In Human Clinical Trial With GLP-1 Implant In Obese And Overweight Individuals In Australia
VANI